1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Eledon Acquires Anelixis Therapeutics

M&A Deal Summary

Eledon Acquires Anelixis Therapeutics

On September 14, 2020, Eledon acquired life science company Anelixis Therapeutics

Acquisition Highlights
  • This is Eledon’s 1st transaction in the Life Science sector.
  • This is Eledon’s 1st transaction in the United States.
  • This is Eledon’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2020-09-14
Target Anelixis Therapeutics
Sector Life Science
Buyer(s) Eledon
Deal Type Add-on Acquisition

Target

Anelixis Therapeutics

Cambridge, Massachusetts, United States
Anelixis Therapeutics, Inc. is a privately held clinical stage biotechnology company developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. Anelixis Therapeutics was founded in 2012 and is based in Cambridge, Massachusetts.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Eledon

Irvine, California, United States
Category Company
Sector Life Science
Employees31
DESCRIPTION

Eledon is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon is based in Irvine, California.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2020 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal